Browse by UCL people
Group by: Type | Date
Number of items: 19.
Article
Adams, D;
Polydefkis, M;
González-Duarte, A;
Wixner, J;
Kristen, AV;
Schmidt, HH;
Berk, JL;
... patisiran Global OLE study group; + view all
(2021)
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
The Lancet Neurology
, 20
(1)
pp. 49-59.
10.1016/S1474-4422(20)30368-9.
|
|
Alrasheed, N;
Lee, L;
Ghorani, E;
Henry, JY;
Conde, L;
Chin, M;
Galas-Filipowicz, D;
... Yong, KL; + view all
(2020)
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4⁺PD-1⁺ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
Clinical Cancer Research
, 26
(13)
pp. 3443-3454.
10.1158/1078-0432.CCR-19-1714.
|
|
Chacko, L;
Boldrini, M;
Martone, R;
Law, S;
Martinez-Naharrro, A;
Hutt, DF;
Kotecha, T;
... Fontana, M; + view all
(2021)
Cardiac Magnetic Resonance–Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid.
Circulation: Cardiovascular Imaging
, 14
(4)
, Article e012506. 10.1161/CIRCIMAGING.121.012506.
|
|
Cohen, OC;
Brodermann, MH;
Dervin, A;
Raja, N;
Marafioti, T;
Otero, S;
Beale, T;
... Morley, S; + view all
(2021)
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre.
European Journal of Haematology
, 106
(2)
pp. 267-272.
10.1111/ejh.13545.
|
|
Cohen, Oliver C;
Ismael, Andreia;
Pawarova, Babita;
Manwani, Richa;
Ravichandran, Sriram;
Law, Steven;
Foard, Darren;
... Wechalekar, Ashutosh D; + view all
(2022)
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
European Heart Journal
, 43
(4)
pp. 333-341.
10.1093/eurheartj/ehab507.
|
|
Cohen, OC;
Brodermann, MH;
Blakeney, IJ;
Mahmood, S;
Sachchithanantham, S;
Ravichandran, S;
Law, S;
... Wechalekar, AD; + view all
(2020)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Amyloid
, 27
(3)
pp. 200-205.
10.1080/13506129.2020.1765768.
|
|
Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
|
|
Cohen, OC;
Law, S;
Lachmann, HJ;
Sharpley, F;
Ravichandran, S;
Mahmood, S;
Sachchithanantham, S;
... Wechalekar, AD; + view all
(2020)
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.
Blood Cancer Journal
, 10
(5)
, Article 60. 10.1038/s41408-020-0325-2.
|
 |
|
Cohen, OC;
Sharpley, F;
Gilbertson, JA;
Wechalekar, AD;
Sachchithanantham, S;
Mahmood, S;
Whelan, CJ;
... Gillmore, JD; + view all
(2020)
The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis.
European Journal of Haematology
, 105
(3)
pp. 352-356.
10.1111/ejh.13458.
|
|
Cohen, OC;
Sharpley, F;
Gillmore, JD;
Lachmann, HJ;
Sachchithanantham, S;
Mahmood, S;
Fontana, M;
... Wechalekar, AD; + view all
(2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis.
British Journal of Haematology
, 189
(4)
pp. 643-649.
10.1111/bjh.16401.
|
|
Cohen, OC;
Wechalekar, AD;
(2020)
Systemic amyloidosis: moving into the spotlight.
Leukemia
, 34
(5)
pp. 1215-1228.
10.1038/s41375-020-0802-4.
|
|
Law, S;
Cohen, O;
Lachmann, H;
Rezk, T;
Gilbertson, J;
Rowczenio, D;
Wechalekar, A;
... Gillmore, J; + view all
(2021)
Renal Transplant Outcomes in Amyloidosis.
Nephrology Dialysis Transplantation
, 36
(2)
pp. 355-365.
10.1093/ndt/gfaa293.
|
|
Law, S;
Petrie, A;
Chacko, L;
Cohen, OC;
Ravichandran, S;
Gilbertson, JA;
Rowczenio, D;
... Gillmore, JD; + view all
(2020)
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
ESC Heart Failure
10.1002/ehf2.12989.
(In press).
|
|
Law, S;
Petrie, A;
Chacko, L;
Cohen, OC;
Ravichandran, S;
Gilbertson, JA;
Rowczenio, D;
... Gillmore, JD; + view all
(2021)
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.
Heart
10.1136/heartjnl-2021-319063.
(In press).
|
|
Manwani, R;
Cohen, O;
Sharpley, F;
Mahmood, S;
Sachchithanantham, S;
Foard, D;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Blood
, 134
(25)
pp. 2271-2280.
10.1182/blood.2019000834.
|
|
Ravichandran, S;
Cohen, OC;
Law, S;
Sachchithanantham, S;
Mahmood, S;
Foard, D;
Fontana, M;
... Wechalekar, AD; + view all
(2021)
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
British Journal of Haematology
, 194
(3)
pp. 587-597.
10.1111/bjh.17636.
|
|
Ravichandran, S;
Cohen, OC;
Law, S;
Foard, D;
Fontana, M;
Martinez-Naharro, A;
Whelan, C;
... Wechalekar, AD; + view all
(2021)
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Blood Cancer Journal
, 11
(6)
, Article 118. 10.1038/s41408-021-00510-7.
|
|
|
Sharpley, FA;
Manwani, R;
Petrie, A;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Martinez De Azcona Naharro, A;
... Wechalekar, AD; + view all
(2021)
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK.
European Journal of Haematology
, 106
(4)
pp. 537-545.
10.1111/ejh.13582.
|
Thesis
|
Cohen, Oliver Charles;
(2024)
Prognostic Markers and Management Strategies in Systemic Amyloidosis.
Doctoral thesis (M.D(Res)), UCL (University College London).
|
|
